schedule

PHARMAC Immunisation Schedule 2017 consultation

Monday, 30 May 2016

In a media release today, PHARMAC announced it is seeking feedback on proposed changes for the National Immunisation Schedule 2017.

Consultation opened today with regard to:

  • Including vaccination of boys in the HPV school vaccination program in the 2017 school year and widening access to HPV vaccination for females and males to the age of 26 years.
  • Universal vaccination against chickenpox for all infants as a part of the childhood immunisation schedule, from 1 July 2017.
  • A number of other changes to the currently listed vaccines including brand changes and a move to a 2-dose schedule for vaccination against rotavirus.

Details are available on the PHARMAC Proposal to amend listings in the National Immunisation Schedule webpage and in the Full consultation document and Annex A.

The consultation period closes at 5pm on 20 June 2016.

Show in archive
Archived: 
0
Archive Date: 

IPOL

IPV

IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.

M-M-R® II

MMR

M-M-R® II is used for primary vaccination and revaccination of children and adults to protect against measles, mumps and rubella.

Act-HIB®

Haemophillus influenzae type b (Hib)

Act-HIB® is used for a booster vaccination at 15 months of age to protect against disease caused by Haemophilus influenzae type b. The vaccine is also used for vaccination of children aged 5 years of age and over and adults with some chronic medical conditions.

ADT™ Booster

Td

ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.

Infanrix®-IPV

DTaP-IPV

Infanrix®-IPV is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis and poliomyelitis. Infanrix®-IPV can also be used for catch-up immunisation for children up to their 10th birthday.

Gardasil®

Human papillomavirus (HPV)

Gardasil® protects against four types of human papillomavirus (HPV) infection. HPV types 6 and 11 cause anogenital warts and HPV types 16 and 18 cause precancerous lesions, mouth, throat, cervical, vaginal, vulvar, penile and anal cancers.

Synflorix®

PCV10

Synflorix® is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by 10 types of streptococcus pneumoniae.

Infanrix®-hexa

DTaP-IPV-HepB/Hib

Infanrix®-hexa is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. Infanrix®-hexa can also be used for catch-up immunisation for children up to their 10th birthday.

Subscribe to RSS - schedule